Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 1Phase 1 1

Status

Recruiting 5Completed 3Unknown 2

Sponsor Class

OTHER 8INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 3Sarcoma 2Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Gastrointestinal Stromal Tumors 1GIST 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × olverembatinib × Clear all
NCT06051409 2026-04-30

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Ascentage Pharma Group Inc.

Phase 3 Recruiting
350 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04501120 2026-04-29

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Ascentage Pharma Group Inc.

Phase 1/2 Recruiting
682 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03594422 2026-04-09

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Ascentage Pharma Group Inc.

Phase 1 Recruiting
100 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT06423911 2025-06-03

POLARIS-2

Ascentage Pharma Group Inc.

Phase 3 Recruiting
285 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting
40 enrolled
Sarcoma

GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡